tbuckley/cabot-search huggingface dataset:
Abstract P262: Receptor-Ligand Functional Interaction Between CD44 and Osteopontin During Calcific Aortic Stenosis: A Molecular Mechanism for Accelerated Biomineralization of Bicuspid Aortic Valve
Authors: Giovanni Ferrari, Juan B Grau, Rachana Sainger, Paolo Poggio, Benjamin C Field, Emanuela Branchetti, William F Seefried, Joseph E Bavaria
Journal: Circulation Research (2011)

Introduction: Calcific aortic valve degeneration (CAVD) is the most common indication for surgical valve replacement in the US. The calcification starts with a Tricuspid Aortic Valve (TAV) or with a Bicuspid Aortic Valve (BAV). Initial phases of the disease, include thickening of the valve, a condition known as aortic valve sclerosis (AVSc), whereas advanced stages, aortic valve stenosis (AVS), are associated with leaflets biomineralization. The biomineralization process, occurring in an accelerated manner in BAV, has not been described in its molecular mechanisms. We reported that Osteopontin (OPN) is implicated in the calcification of dystrophic and ectopic sites. Here we investigate the interaction between OPN, and one of its functional regulators, CD44, during valve degeneration in TAV and BAV patients. Methods: Five groups of 10 subjects each (TAV: control, AVSc, AVS; BAV: control and AVS) were selected from our tissue biorepository according to echocardiographic analysis, inclusion/exclusion criteria, and/or intra-op observations. Histological studies, cellular and molecular analysis, and in situ proximity-ligation-assay (PLA) on surgically resected tissues were used to investigate the functional interaction between OPN and CD44. Results: 1) In vitro calcification assays shows that OPN protects against calcification through CD44 interaction. 2) OPN and CD44 levels are elevated in the leafelts of BAV patients, both stenotic patients and controls. In TAV, AVSc and AVS patients shows elevated levels of OPN and CD44 when compared to controls. 3) In situ PLA assay displayed a direct interaction between CD44 and OPN in BAV patients, in both stenotic patients and controls, and in TAV AVSc and AVS patients. Healthy, non-calcified TAV subjects, shows barely detectible OPN-CD44 interaction. Conclusion: OPN-CD44 direct interaction correlate with the severity of biomineralization in TAV patients. Conversely, in BAV we demonstrate a direct interaction between OPN and CD44 in both stenotic and non-calcified tissues. These results are aims to elucidate the mechanisms behind the accelerated biomineralization of BAV compared to TAV, and generate important insights into the development of diagnostic and therapeutic approached for CAVD.
Axial spondyloarthritis: new advances in diagnosis and management
Authors: Christopher Ritchlin, Iannis E Adamopoulos
Journal: BMJ (2021)

Abstract Axial spondyloarthritis (axSpA) is an inflammatory disease of the axial skeleton associated with significant pain and disability. Previously, the diagnosis of ankylosing spondylitis required advanced changes on plain radiographs of the sacroiliac joints. Classification criteria released in 2009, however, identified a subset of patients, under the age of 45, with back pain for more than three months in the absence of radiographic sacroiliitis who were classified as axSpA based on a positive magnetic resonance imaging or HLAB27 positivity and specific clinical features. This subgroup was labeled non-radiographic (nr)-axSpA. These patients, compared with those identified by the older New York criteria, contained a larger percentage of women and demonstrated less structural damage. However, their clinical manifestations and response to biologics were similar to radiographic axSpA. The discovery of the interleukin (IL) IL-23/IL-17 pathway revealed key molecules involved in the pathophysiology of axSpA. This discovery propelled the generation of antibodies directed toward IL-17A, which are highly effective and demonstrate treatment responses in axSpA that are similar to those observed with anti-TNF agents. The finding that agents that block IL-23 were not effective in axSpA came as a surprise and the potential underlying mechanisms underlying this lack of response are discussed. New agents with dual inhibition of the IL-17A and F isoforms and some oral small molecule agents that target the Jak-STAT pathway, have also shown efficacy in axSpA.
The $50 000 Physical
Authors: Michael B. Rothberg
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 15161: Increased Right Atrial Stiffness in Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension
Authors: Jessie van Wezenbeek, Arno van der Bovenkamp, Jeroen N Wessels, Sophia-Anastasia Mouratoglou, Marie Jose Goumans, anton vonk noordegraaf, Harm J Bogaard, M L Handoko, Frances S De Man
Journal: Circulation (2020)

Background: Patients with Heart Failure with preserved Ejection Fraction (HFpEF) and Pulmonary Hypertension (PH) have increased right atrial (RA) pressures. Whether the higher RA pressures are related to increased afterload or overall stiffening of the heart is unknown. The aim of this study is to gain further insight into the right atrium in HFpEF-PH. Methods: This is a retrospective analysis of patients with HFpEF (no PH), HFpEF-PH and Pulmonary Arterial Hypertension (PAH) that underwent right heart catheterization and cardiac magnetic resonance (CMR) imaging. CMR was used to determine RA function by quantifying volume and strain on the 4-chamber view. Total, passive and active RA emptying fraction (RAEF) were calculated. RA stiffness was calculated by determining the slope of maximum and minimum pressure during v-wave and minimal and maximal RA volumes. Groups were compared with ANOVA and post-hoc comparison with Bonferroni correction. Results: 176 patients were included: 13 HFpEF, 33 HFpEF-PH and 130 PAH patients. Although afterload was lower in PAH and higher in HFpEF patients, as shown by mean pulmonary arterial pressure (mPAP) (41 ± 2 mmHg in HFpEF-PH vs 53 ± 21 mmHg in PAH vs 19 ± 1 mmHg in HFpEF, p&lt;0.001) and pulmonary vascular resistance (PVR) (2.3 ± 0.3 wu/m 2 in HFpEF-PH vs 5.7 ± 0.2 wu/m 2 in PAH vs 0.4 ± 0.06 wu/m 2 in HFpEF, p&lt;0.001), mean RA pressure was significantly higher in HFpEF-PH patients compared to both groups (Figure 1A). HFpEF-PH patients had significantly increased RA stiffness compared to HFpEF and PAH patients (Figure 1B). Total RAEF was reduced in HFpEF-PH compared to PAH and HFpEF patients: passive RAEF was similar, but active RAEF was slightly reduced in HFpEF-PH (Figure 1C). This was in line with measurements of RA longitudinal strain (Figure 1D). Conclusions: Despite lower afterload, HFpEF-PH patients have worse RA function and increased RA stiffness compared to PAH. Higher RA pressures in HFpEF-PH may reflect additional stiffening of the heart.
Endotracheal, Endobronchial, and Vocal Cords Metastases From Lung Cancer Detected by 18F-FDG PET/CT
Authors: JingXing Xiao, Min Su, Dong Wang
Journal: Clinical Nuclear Medicine (2021)

A 61-year-old man with a history of lung cancer initially treated 3 years prior presented with a new onset of cough for 1-month and 2-week hoarseness. FDG PET/CT revealed multiple hypermetabolic lesions in the endotracheal, endobronchial, and vocal cords. Subsequently, immunostaining confirmed that all lesions were metastatic squamous cell carcinomas originating from the patient's primary lung squamous cell carcinoma.
Abstract 15585: Irregular Protrusion is Predictor for Development of Neoatherosclerosis After 2nd and 3rd Generation Drug-Eluting Stent Implantation - Optical Coherence Tomography Study
Authors: Kyosuke Yanagawa, Ryu Shutta, Yutaka Matsuhiro, Hitoshi Nakamura, Koji Yasumoto, Akihiro Tanaka, Naotaka Okamoto, Yasuharu Matsunaga, Daisuke Nakamura, Masamichi Yano, Masaki Yamato, Yasuyuki Egami, Jun Tanouchi, Masami Nishino
Journal: Circulation (2019)

Background: Several studies using optical coherence tomography (OCT) have shown that the prevalence of irregular protrusion in post-stenting OCT findings is associated with characteristics of neoin...
Arsenic: A Global Environmental Challenge
Authors: Qiao Yi Chen, Max Costa
Journal: The Annual Review of Pharmacology and Toxicology (2021)

Arsenic is a naturally occurring metalloid and one of the few metals that can be metabolized inside the human body. The pervasive presence of arsenic in nature and anthropogenic sources from agricultural and medical use have perpetuated human exposure to this toxic and carcinogenic element. Highly exposed individuals are susceptible to various illnesses, including skin disorders; cognitive impairment; and cancers of the lung, liver, and kidneys. In fact, across the globe, approximately 200 million people are exposed to potentially toxic levels of arsenic, which has prompted substantial research and mitigation efforts to combat this extensive public health issue. This review provides an up-to-date look at arsenic-related challenges facing the global community, including current sources of arsenic, global disease burden, arsenic resistance, and shortcomings of ongoing mitigation measures, and discusses potential next steps.
COVID-19 media coverage decreasing despite deepening crisis
Authors: Olivia Pearman, Maxwell Boykoff, Jeremiah Osborne-Gowey, Midori Aoyagi, Anne Gammelgaard Ballantyne, Patrick Chandler, Meaghan Daly, Kaori Doi, Rogelio Fernández-Reyes, Isidro Jiménez-Gómez, Ami Nacu-Schmidt, Lucy McAllister, Marisa McNatt, Gabi Mocatta, Lars Kjerulf Petersen, Anne Hege Simonsen, Andreas Ytterstad
Journal: The Lancet Planetary Health (2021)
Endoscopes used in positive and critically ill patients are SARS-CoV-2 negative at virological assessment
Authors: Ivo Boškoski, Anna Di Gemma, Maria Valeria Matteo, Fabio Grilli, Paola Cattani, Guido Costamagna
Journal: Gut (2021)

The risk of SARS-CoV-2 transmission in endoscopy is not only between patients and endoscopy staff but is also through inadequately reprocessed endoscopes. There are no studies that could confirm the efficacy of current ways of endoscope reprocessing on the elimination of SARS-CoV-2. The aim of this pilot study was to evaluate the efficacy of high disinfection of endoscopes with peracetic acid on eliminating SARS-CoV-2, but surprisingly we found that the virus cannot be detected on any part of endoscopes used in critically ill patients due to SARS-CoV-2 and this was the same for all types of endoscopies and procedures. If confirmed in larger studies, these findings will probably open a new scenario in the overall understanding of the real impact of the virus.
Abstract 10335: Therapeutic Ultrasound Improves Myocardial Blood Flow And Reduces Infarct Size in a Canine Model of Coronary Microthromboembolism
Authors: Mrinal Yadava, Dai-Trang E Le, Igor Dykan, Matthew Nugent, Azzdine Y Ammi, David Giraud, Yan Zhao, Jessica Minnier, Sanjiv Kaul
Journal: Circulation (2019)

Introduction: Therapeutic ultrasound (TUS) has been used to lyse coronary thrombus. There has been no study examining the effect of TUS specifically on myocardial microthromboemboli seen in acute m...
Visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system against immune-associated nephropathy without glucocorticoid side effect
Authors: Kui Fan, Li Zeng, Jing Guo, Shuqin Xie, Yuan Yu, Jianwei Chen, Jin Cao, Qinyanqiu Xiang, Siliang Zhang, Yuanli Luo, Qingyue Deng, Qin Zhou, Yan Zhao, Lan Hao, Zhigang Wang, Ling Zhong
Journal: Theranostics (2021)

Glucocorticoids are widely used in the treatment of nephritis, however, its dose-dependent side effects, such as the increased risk of infection and metabolic disturbances, hamper its clinical use. This study reports a visualized podocyte-targeting and focused ultrasound responsive glucocorticoid nano-delivery system (named as Dex/PFP@LIPs-BMS-α), which specific delivers dexamethasone (Dex) to podocyte targets and reduces systemic side effects. Methods: The glucocorticoid nano-delivery system was synthesized by a lipid thin film and a simple facile acoustic-emulsification method. This glucocorticoid nano-delivery system used BMS-470539 (BMS-α), a synthetic compound, as a "navigator" to specifically identify and target the melanocortin-1 receptor (MC-1R) on podocytes. The loaded perfluoropentane (PFP) realizes the directed "explosion effect" through ultrasound-targeted microbubble destruction (UTMD) technology under the coordination of low intensity focused ultrasound (LIFU) to completely release Dex. Results: Both in vitro and in vivo experiments have demonstrated that Dex/PFP@LIPs-BMs-α accurately gathered to podocyte targets and improved podocyte morphology. Moreover, in vivo, proteinuria and serum creatinine levels were significantly reduced in the group treated with Dex/PFP@LIPs-BMS-α, and no severe side effects were detected. Furthermore, Dex/PFP@LIPs-BMS-α, with capabilities of ultrasound, photoacoustic and fluorescence imaging, provided individualized visual guidance and the monitoring of treatment. Conclusion: This study provides a promising strategy of Dex/PFP@LIPs-BMS-α as effective and safe against immune-associated nephropathy.
Abstract 15565: Thermoreactive Implant for Superior Vena Cava Isolation
Authors: Glenn Van Langenhove, Zoe Van Langenhove, Samuel Van Langenhove, Ahmed Soliman Hegazy, Roberto Baglini, Ernest C Madu
Journal: Circulation (2019)

Introduction: Pulmonary vein isolation (PVI) remains the cornerstone of invasive treatment of paroxysmal atrial fibrillation in humans. As the pig PV anatomy is unattractive to test novel therapies...
Health education through football (soccer): the ‘11 for health’ programme as a success story on implementation: learn, play and have fun!
Authors: Jane S Thornton, Jiri Dvorak, Irfan Asif
Journal: British Journal of Sports Medicine (2021)

Physical inactivity is one of the biggest public health threats of this century and greatly increases the risk of non-communicable diseases. This is especially true for our children and youth, where fallout from current pandemic lockdowns has disrupted access to physical activity and sport. Virtual classrooms translated into forfeited recess and free play while kids were thrown in front of computer screens and confined to a sedentary lifestyle. In large urban centres with many living in high rises, lockdowns on playgrounds and parks removed options for running or playing. Prior to the pandemic, physical inactivity was already a critical issue—a WHO survey of 1.6 million participants in 146 countries revealed that 81% of children and adolescents aged 11–17 were not active enough for optimal health.1

In response, WHO created the global action plan on physical activity, a call to action for policy change and effective implementation, where school-based policy initiatives are an essential component to create a more active society.2

In a recent …
A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Mucosal Melanoma (NCT02023710).
Authors: Xinan Sheng, Lu Si, Zhihong Chi, Chuanliang Cui, Si Ming Li, Li Li Mao, BIN LIAN, Bixia Tang, Xieqiao Yan, Xuan Wang, Yan Kong, Jie Dai, Xiaoshi Zhang, Xin Song, Jun Guo
Journal: Journal of Clinical Oncology (2016)

e21043 Background: There was no standard treatment for advanced mucosal melanoma patients. BEAM study have demonstrated the effectivity and safety of bevacizumab combined with carboplatin plus paclitaxel in patients with previously untreated metastatic melanoma. This study was to evaluate the activity of bevacizumab combined with carboplatin plus paclitaxel in Patients with Previously Untreated Advanced Mucosal Melanoma. Methods: This study is an open-label, multicenter, randomized phase II trial. Eligible patients had metastatic, or unresectable mucosal melanoma without any systemic therapy. Additional inclusion criteria included ≥ 1 measurable disease、ECOG PS 0/1, and adequate organ functions. The patient with mutations in c-KIT or BRAF-V600E will be excluded from this study. Patients were randomly allocated in a 1:1 ratio to receive bevacizumab (CPB arm, 5mg/kg every two weeks) or placebo (CP arm) with carboplatin (area under the curve, 5) plus paclitaxel (175 mg/m2), all by intravenous infusion. Treatment was continued for both groups until disease progression, unacceptable toxicity, death, or withdrawal of consent. The primary study endpoint is progress-free survival (PFS). Overall survival, disease control rate, and safety will also be assessed. Results: The first patient visit was December 1, 2013; ninety-four of a planned 182 evaluable pts have been enrolled; 63.8% female, median age was 59 years old, and randomly assigned to the CBP (n = 46) or CP arm (n = 48). The objective response rate was 10.9% and 4.1% respectively. The median progression-free survival was 5.0 months and 3.0 months respectively (p = 0.028). The median overall survival was 12.0 months and 11.5 months respectively (p = 0.754). Treatment emergent grade 3 or 4 adverse events were neutropenia (13.0%), hypertension (4.3%), proteinuria (4.3%) in the PCB arm; and neutropenia (10.4%) in the PC arm. Conclusions: This is the largest study about advanced mucosal melanoma which demonstrated that bevacizumab in combination with carboplatin plus paclitaxel is active and safe as first line therapy in advanced mucosal melanoma. Clinical trial information: NCT02023710.
OFP01.02 KEYNOTE-021 Cohort G Long-Term Follow-up: First-Line (1L) Pemetrexed and Carboplatin (PC) with or without Pembrolizumab for Advanced Nonsquamous NSCLC
Authors: M.M. Awad, S.M. Gadgeel, H. Borghaei, A. Patnaik, J. Chih-Hsin Yang, S.F. Powell, R.D. Gentzler, R.G. Martins, J.P. Stevenson, M. Altan, S.I. Jalal, A. Panwalkar, M. Gubens, L.V. Sequist, S. Saraf, B. Zhao, B. Piperdi, C.J. Langer
Journal: Journal of Thoracic Oncology (2021)
β-Trace Protein Versus Cystatin C: Which Is a Better Surrogate Marker of Renal Function Versus Prognostic Indicator in Cardiovascular Diseases?⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.
Authors: Horng H. Chen
Journal: Journal of the American College of Cardiology (2011)
Proteinase release from activated neutrophils in mechanically ventilated patients with non-COVID-19 and COVID-19 pneumonia
Authors: Seda Seren, Lohann Derian, Irem Keleş, Antoine Guillon, Adam Lesner, Loïc Gonzalez, Thomas Baranek, Mustapha Si-Tahar, Sylvain Marchand-Adam, Dieter E. Jenne, Christophe Paget, Youenn Jouan, Brice Korkmaz
Journal: European Respiratory Journal (2021)

<b>COVID-19 ARDS is associated with release of biologically active neutrophil elastase-related proteinases to the airways and blood at a comparable level to non-COVID ARDS</b>https://bit.ly/3nihveh
Reply to Salma Kaochar, Nicholas Mitsiades’ Letter to the Editor re: Umang Swami, Pedro Isaacsson Velho, Roberto Nussenzveig, et al. Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Eur Urol 2020, 78:652–6. Can Mutant SPOP Become an Actionable Biomarker for Precision Oncology Management of Prostate Cancer?
Authors: Umang Swami, Emmanuel S. Antonarakis, Neeraj Agarwal
Journal: European Urology (2021)
How we treat mature B-cell neoplasms (indolent B-cell lymphomas)
Authors: Melissa Lumish, Lorenzo Falchi, Brandon S. Imber, Michael Scordo, Gottfried von Keudell, Erel Joffe
Journal: Journal of Hematology & Oncology (2021)

Mature B cell neoplasms, previously indolent non-Hodgkin lymphomas (iNHLs), are a heterogeneous group of malignancies sharing similar disease courses and treatment paradigms. Most patients with iNHL have an excellent prognosis, and in many, treatment can be deferred for years. However, some patients will have an accelerated course and may experience transformation into aggressive lymphomas. In this review, we focus on management concepts shared across iNHLs, as well as histology-specific strategies. We address open questions in the field, including the influence of genomics and molecular pathway alterations on treatment decisions. In addition, we review the management of uncommon clinical entities including nodular lymphocyte-predominant Hodgkin lymphoma, hairy cell leukemia, splenic lymphoma and primary lymphoma of extranodal sites. Finally, we include a perspective on novel targeted therapies, antibodies, antibody-drug conjugates, bispecific T cell engagers and chimeric antigen receptor T cell therapy.
Effect of Oral Moxifloxacin vs Intravenous Ertapenem Plus Oral Levofloxacin for Treatment of Uncomplicated Acute Appendicitis
Authors: Suvi Sippola, Jussi Haijanen, Juha Grönroos, Tero Rautio, Pia Nordström, Tuomo Rantanen, Tarja Pinta, Imre Ilves, Anne Mattila, Jukka Rintala, Eliisa Löyttyniemi, Saija Hurme, Ville Tammilehto, Harri Marttila, Sanna Meriläinen, Johanna Laukkarinen, Eeva-Liisa Sävelä, Heini Savolainen, Tomi Sippola, Markku Aarnio, Hannu Paajanen, Paulina Salminen
Journal: JAMA (2021)

Antibiotics are an effective and safe alternative to appendectomy for managing uncomplicated acute appendicitis, but the optimal antibiotic regimen is not known.
Racial Disparities in Cardiovascular Procedure Outcomes: Turn Down the Volume⁎⁎Editorials published in the Journal of the American College of Cardiologyreflect the views of the authors and do not necessarily represent the views of JACCor the American College of Cardiology.
Authors: John S. Rumsfeld, Andrew J. Epstein
Journal: Journal of the American College of Cardiology (2006)